IL6 and myocardial infarction: In CANTOS trial (47), the monoclonal human antibody canakinumab decreased high-sensitivity C-reactive protein (hsCRP) and IL-6 levels and main cardiovascular events, in the long term after myocardial infarction (48, 49).